Resources & Guides

Retatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

Retatrutide is not approved in any country as of June 2026. It remains investigational, in Phase 3 TRIUMPH trials. Here is the regulatory status across the FDA, EMA, MHRA, TGA, and Health Canada, and what approved versus available actually means.

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans to submit a Biologics License Application (BLA) in Q1 2027, and the most defensible approval window is late 2027 to 2028. Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.

Tirzepatide has two FDA-approved brand names, both from Eli Lilly: Mounjaro for type 2 diabetes (May 2022, NDA 215866) and Zepbound for chronic weight management (November 2023, NDA 217806). Same molecule, two indications, two boxes.

Mounjaro (tirzepatide) is Eli Lilly's once-weekly injectable for type 2 diabetes, FDA-approved May 2022. The first dual GIP/GLP-1 receptor agonist, with a 2.5 to 15 mg dose ladder and SURPASS trial backing.

TRIUMPH-4 showed 28.7% weight loss at 68 weeks in December 2025. Seven more retatrutide trials report in 2026. Here is the full TRIUMPH program map, how to enroll, and what the timeline means for FDA approval.

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans a BLA filing in Q1 2027, with approval possible in 2027-2028. In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

Compounded tirzepatide costs a fraction of Mounjaro or Zepbound — see our full <a href="/resources/tirzepatide-cost" style="color: #2563eb;">tirzepatide cost guide</a> but sits at the center of an ongoing legal battle between Eli Lilly, compounding pharmacies, and the FDA. This guide covers the regulatory landscape after the October 2024 shortage removal, how to source safely, dosing considerations, reconstitution, storage, and what the court rulings mean for availability.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides, why compounded retatrutide is not a lawful option, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.